Information Provided By:
Fly News Breaks for October 27, 2016
Q
Oct 27, 2016 | 05:33 EDT
Piper Jaffray analyst Sean Wieland downgraded Quintiles to Neutral saying risks from the merger with IMS are not priced in. Consolidation of data suppliers may increase data acquisition costs in 2018, Wieland tells investors in a research note. Further, he believes the business of clinical trial recruitment will get more challenging. The analyst lowered his price target for Quintiles to $72 from $75.
News For Q From the Last 2 Days
There are no results for your query Q